Table 4

Immunological response in subjects who received Pfizer

Withhold therapyContinue therapyControlsTotal
Detectable SARS-CoV2 antibodies*
Post first vaccine dose37/44 (84.1)31/48 (64.58)27/27 (100)95/119 (79.83)
 Withhold versus continue (p=0.056)
 Withhold versus controls (p=0.039)
 Continue versus controls (p=0.000)
Post second vaccine dose42/42 (100)47/49 (95.9)27/27 (100)116/118 (98.31)
 Withhold versus continue (p=0.497)
 Withhold versus controls
 Continue versus controls (p=0.413)
Mean SARS-CoV2 Ab titre†
Post first vaccine dose7.36 (9.79)4.94 (7.19)11.05 (11.82)7.24 (9.59)
 Withhold versus continue (p=0.019)3.4 (8.7)1.85 (7.1)5.1 (10.2)3.4 (8.8)
 Withhold versus controls (p=0.052)
 Continue versus controls (p=0.000)
Post second vaccine dose136.02 (169.68)76.18 (77.63)133.58 (166.26)110.40 (139.53)
 Withhold versus continue (p=0.032)73.7 (111.3)50.8 (92)66.8 (78.3)66.8 (97.2)
 Withhold versus controls (p=0.980)
 Continue versus controls (p=0.033)
  • Data are presented as proportions (%) or mean (SD) and median (IQR).

  • *Using Fisher’s exact test with significance cut-off 5%.

  • †Using Wilcoxon-Mann-Whitney U test with significance cut-off 5%.

  • Ab, antibody.